May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
CD200R Signalling Controls Macrophage Activation During Experimental Autoimmune Uveoretinitis
Author Affiliations & Notes
  • D. Copland
    University of Bristol, Bristol, United Kingdom
    Clinical Sciences,
  • C. J. Calder
    University of Bristol, Bristol, United Kingdom
    Cellular and Molecular Medicine,
  • B. J. E. Raveney
    University of Bristol, Bristol, United Kingdom
    Cellular and Molecular Medicine,
  • J. Phillips
    SP Biopharma, Palo Alto, California
  • H. Cherwinski
    SP Biopharma, Palo Alto, California
  • M. Jenmalm
    SP Biopharma, Palo Alto, California
  • J. D. Sedgwick
    SP Biopharma, Palo Alto, California
  • L. B. Nicholson
    University of Bristol, Bristol, United Kingdom
    Cellular and Molecular Medicine,
  • A. D. Dick
    University of Bristol, Bristol, United Kingdom
    Clinical Sciences,
  • Footnotes
    Commercial Relationships D. Copland, None; C.J. Calder, None; B.J.E. Raveney, None; J. Phillips, SP Biopharma, E; H. Cherwinski, SP Biopharma, E; M. Jenmalm, SP Biopharma, E; J.D. Sedgwick, SP Biopharma, E; L.B. Nicholson, None; A.D. Dick, SP Biopharma, R.
  • Footnotes
    Support National Eye Research Centre, UK
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 5203. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      D. Copland, C. J. Calder, B. J. E. Raveney, J. Phillips, H. Cherwinski, M. Jenmalm, J. D. Sedgwick, L. B. Nicholson, A. D. Dick; CD200R Signalling Controls Macrophage Activation During Experimental Autoimmune Uveoretinitis. Invest. Ophthalmol. Vis. Sci. 2007;48(13):5203.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To determine whether stimulating CD200 receptor (CD200R) signalling using an agonist mAb, DX109 can modulate macrophage activation and thus ameliorate the severity of Experimental Autoimmune Uveoretinitis (EAU).Background:Macrophage responses are regulated by stimulatory and inhibitory signalling delivered by secreted factors or cell surface receptors. It has been previously demonstrated that ligation of CD200R by the widely distributed CD200 molecule mediates inhibition of macrophage activation. The murine model of human inflammatory eye disease, EAU, is characterized by structural retinal damage mediated by infiltrating macrophages. CD200-/- mice display increased susceptibility to autoimmunity and earlier onset aggressive disease, suggesting a role for CD200R signalling in preventing autoimmunity.

Methods:: EAU was induced in B10.RIII mice by immunization with hRBP-3161-180. At certain time-points, eyes were enucleated and spleens dissected for histological disease and functional assessment, respectively. As a therapeutic intervention, DX109 was systemically administered on day 10, 14 and 18 post-immunization. Efficacy of local treatment with DX109 was also assessed by intra-vitreal injection at day 10 and 14. To determine the mechanism of DX109 action, in vitro experiments were performed where bone marrow derived macrophages were treated with DX109 prior to activation.

Results:: Systemic administration of DX109 agonist CD200R mAb suppressed EAU, despite normal T cell proliferative responses. Local administration of DX109 during efferent phase of disease effectively suppressed disease. Pre-incubation of macrophages with DX109 resulted in suppression of in vitro activation as measured by nitric oxide and IL-6 production.

Conclusions:: These experiments demonstrate that promoting CD200R signalling can successfully prevent full expression of IFNγ-mediated macrophage activation and protect against tissue damage during autoimmune responses in the retina.

Keywords: autoimmune disease • inflammation • uveitis-clinical/animal model 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×